Cox Capital Mgt LLC Sells 88 Shares of Zoetis Inc. (NYSE:ZTS)

Cox Capital Mgt LLC trimmed its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 0.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 11,870 shares of the company’s stock after selling 88 shares during the period. Cox Capital Mgt LLC’s holdings in Zoetis were worth $1,934,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in ZTS. Darwin Wealth Management LLC acquired a new stake in Zoetis during the third quarter valued at approximately $31,000. First Personal Financial Services acquired a new stake in Zoetis in the 3rd quarter valued at $33,000. Capital Performance Advisors LLP bought a new stake in Zoetis in the third quarter valued at $33,000. Dunhill Financial LLC raised its stake in Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares in the last quarter. Finally, Quarry LP lifted its holdings in shares of Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after acquiring an additional 153 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. increased their target price on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Leerink Partners assumed coverage on Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price on the stock. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Stifel Nicolaus decreased their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Finally, UBS Group assumed coverage on shares of Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective on the stock. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $211.89.

Zoetis Trading Down 1.2 %

Shares of NYSE ZTS opened at $164.31 on Wednesday. The company’s 50 day simple moving average is $171.31 and its 200 day simple moving average is $180.16. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.53. The firm has a market capitalization of $74.13 billion, a P/E ratio of 30.89, a P/E/G ratio of 2.91 and a beta of 0.89.

Zoetis (NYSE:ZTS) last posted its earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.12. The company had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The company’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same period in the previous year, the company earned $1.36 EPS. On average, analysts predict that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be issued a dividend of $0.50 per share. The ex-dividend date is Tuesday, January 21st. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 annualized dividend and a yield of 1.22%. Zoetis’s payout ratio is currently 37.59%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.